Latest News and Press Releases

Following positive top-line results from pivotal Phase 3 trial of SPK-RPE65 for genetic blinding conditions, company significantly expands and advances gene therapy pipelineBegins 2016 with a cash...

PHILADELPHIA, March 07, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) today announced that it has acquired Dublin, Ireland-based Genable Technologies, a private gene therapy innovator...

PHILADELPHIA, March 02, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that Jeffrey D. Marrazzo, co-founder and chief executive officer, is presenting at...

PHILADELPHIA, March 02, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, March 9, 2016 at 8:30 a.m. Eastern to report...

PHILADELPHIA, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) today announced the launch of aSharedVision (www.aSharedVision.com), a new online resource designed to help...

Data from five clinical programs and numerous regulatory milestones expected over the next 18 months------------------Strategic vision driven by Spark's fully integrated and validated gene therapy...

PHILADELPHIA, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (NASDAQ:ONCE) announced today that Lota Zoth, CPA, a long-time financial executive at multiple publicly listed companies,...

PHILADELPHIA, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that Jeffrey D. Marrazzo, co-founder and chief executive officer, is presenting...

PHILADELPHIA, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the pricing of an underwritten public offering of 3,000,000 shares of its common...

PHILADELPHIA, Dec. 14, 2015 (GLOBE NEWSWIRE) -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that it has commenced an underwritten public offering of 3,000,000 shares of its...